Patritumab Deruxtecan Bla Submission Receives Complete Response Letter From FDA Due to Inspection Findings at Third-Party Manufacturer
Patritumab Deruxtecan Bla提交收到FDA的完全回覆信,因第三方製造商的檢查結果而產生了發現。
Patritumab Deruxtecan Bla Submission Receives Complete Response Letter From FDA Due to Inspection Findings at Third-Party Manufacturer
Patritumab Deruxtecan Bla提交收到FDA的完全回覆信,因第三方製造商的檢查結果而產生了發現。
譯文內容由第三人軟體翻譯。